Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -211.1% | n/a |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | 6.3 | n/a |
PEG | n/a | n/a |
Pr/Revenue | 19.7 | n/a |
Pr/Book | 17.2 |
Latest | F'cast | |
---|---|---|
Revenue | 39.9% | n/a |
PBT | n/a | n/a |
EPS | -80.3% | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Jun-21 | 1.60 | (2.91) | (3.92)p | n/a | n/a | n/a | n/a | 0.0% |
30-Jun-22 | 4.04 | (2.64) | (3.24)p | n/a | n/a | n/a | n/a | 0.0% |
30-Jun-23 | 1.75 | (8.30) | (11.35)p | n/a | n/a | n/a | n/a | 0.0% |
30-Jun-24 | 0.86 | (3.14) | 0.71p | 0.9 | n/a | n/a | n/a | 0.0% |
30-Jun-25 | 1.20 | (2.57) | 0.14p | 2.9 | n/a | -80% | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Full Year Results for the 12mths to 30 June 2025 | 14-Oct-2025 | 07:00 | RNS |
New contract with top 10 pharma | 13-Oct-2025 | 07:00 | RNS |
Notice of Results, Analyst & Investor Presentation | 10-Oct-2025 | 07:00 | RNS |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 0.96p |
Change Today | 0.077p |
% Change | 8.77 % |
52 Week High | 1.30 |
52 Week Low | 0.21 |
Volume | 6,737,294 |
Shares Issued | 2,696.98m |
Market Cap | £25.81m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
13:05 | 84 @ 1.05p |
12:46 | 216,630 @ 0.98p |
12:29 | 10,000 @ 0.98p |
12:17 | 15 @ 1.05p |
12:13 | 250,000 @ 1.02p |
CEO | Arron Tolley |
CFO | Andrew Rapson |
You are here: research